2 results match your criteria: "Baoji High-Tech Hospital Baoji 721000[Affiliation]"
Predictive value of the triglyceride-glucose index for no-reflow phenomenon after percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction complicated by metabolic syndrome.
Am J Transl Res
October 2024
Endocrine Department, Baoji High-Tech Hospital Baoji 721000, Shaanxi, China.
Objective: Acute ST-segment elevation myocardial infarction (STEMI) remains a major contributor to morbidity and mortality worldwide. The no-reflow phenomenon following percutaneous coronary intervention (PCI) complicates the clinical outcome of STEMI. This study aimed to identify a valuable predictor for no-reflow phenomenon.
View Article and Find Full Text PDFEarly use of SGLT2 inhibitors reduces the progression of diabetic kidney disease: a retrospective cohort study.
Am J Transl Res
September 2024
Nephrology Department, Baoji High Tech Hospital Baoji 721000, Shaanxi, China.
Article Synopsis
- The study aimed to assess the effectiveness of SGLT2 inhibitors, particularly dapagliflozin, in halting the progression of diabetic kidney disease and improving renal health management for patients with diabetes.
- A retrospective analysis was performed on 178 diabetic kidney disease patients, comparing those who received early versus late treatment with dapagliflozin, focusing on various health markers such as blood glucose levels and renal function.
- Results indicated that early treatment significantly improved blood glucose and renal function compared to late treatment, with both groups showing similar rates of adverse reactions (6.82% for early vs. 10.00% for late), suggesting the advantage of initiating SGLT2 inhibitors earlier in diabetic patients.